ONC · BeOne Medicines Ltd.
$376.86
+7.71 (+2.09%)
At close · Aug 19
Market Cap
$535.83B
Shares
1.48B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$376.86
Open$371.56
Day$371.05–379.20
52W close$260.27–377.47
Avg vol 30d420K
Short int881K · 0.1% float · 2.4d
Short vol34%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+22%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+17%
trailing
YTD return
+24%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $310 › 200d $316 — 200d above 50d
Institutional flow
Distributing
-0% holders QoQ · +46 funds added
Insider flow
Distributing
Net -$8.2M over 90 days · 100% sells
Short interest
Falling
0.06% of float · ▼ -5.0% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
282 holders — near 3-yr high, broad support
Squeeze score
33
low risk · 0–100
Fundamentals
Revenue growth
+22179%
Y/Y
Gross margin
1961%
contracting
EPS growth
+140%
Y/Y
Free cash flow
$941.7M
Valuation
P/E 823.9
rich
Balance sheet
$3.5B
net cash
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
2.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Total revenue
· Full Year 2026
$6.3B – $6.5B
GAAP operating expenses (combined R&D and SG&A)
· Full Year 2026
$4.7B – $4.9B
GAAP operating income
· Full Year 2026
$750M – $850M
Non-GAAP operating income
· Full Year 2026
$1.45B – $1.55B
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
Total Revenue
· Full Year 2025
$5.1B – $5.3B
GAAP Operating Expenses (R&D and SG&A)
· Full Year 2025
$4.1B – $4.3B
Guided vs delivered
· last 1 settled
Total Revenue
Full Year 2025
guided $5.1B – $5.3B
$5.34B
Beat +2.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+22%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $310 › 200d $316 — 200d above 50d
Institutional flow
Distributing
-0% holders QoQ · +46 funds added
Insider flow
Distributing
Net -$8.2M over 90 days · 100% sells
Short interest
Falling
0.06% of float · ▼ -5.0% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
282 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $260
Now $377 · 99%
Range high $377
vs 200-day avg +19%
vs 50-day avg +22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Amgen in-licensed products global sales | 157M | the second quarter of 2026 | — |
|
|
|||
| BRUKINSA global sales | 1.2B | the second quarter | — |
|
|
|||
| BRUKINSA U.S. sales | 893M | the second quarter of 2026 | — |
|
|
|||
| Free Cash Flow (Non-GAAP) non-GAAP | $595.89M | Six Months Ended June 30, 2026 | — |
| Gross Margin as a percentage of global product sales (GAAP) | 90% | the second quarter of 2026 | — |
|
|
|||
| SG&A expenses as a percentage of product sales | 35% | the second quarter of 2026 | — |
|
|
|||
| TEVIMBRA global sales | 229M | the second quarter of 2026 | — |
| Gross Margin | 89% | first quarter of 2026 | — |
| Adjusted net income (loss) non-GAAP | $917.6M | full year | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income (loss) 286.93M
+510.25M Share-based compensation expenses
+131.62M Depreciation
+10.07M Amortization of intangibles
+893K Other
+75.63M Impairment of equity investments
+24.78M Discrete tax items
-122.56M Income tax effect of non-GAAP adjustments
= Adjusted net income (loss) 917.6M
|
|||
| Gross Margin as a percentage of global product sales (Adjusted) non-GAAP | 87.8% | full year | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ONC
this stock
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$56.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ONC | +5.0% | +17.8% | +16.9% | +19.3% | +24.0% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +5.4% | +14.9% | +5.3% | +16.3% | +11.3% |
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
276 filings
253 filers
Visit website
Investor relations